Frankfurt
06.06.25 | 08:01
0,272 Euro
-5,88 % -0,017
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | AlzeCure Pharma to present at Redeye Investor Forum on June 11 | 164 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 4, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| Di | AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm on June 10 | 197 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 3, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 14.05. | Communiqué from the Annual General Meeting of AlzeCure Pharma on 14 May 2025 | 221 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 14, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - Today, 14 May 2025, the annual general meeting was held in AlzeCure Pharma AB (publ) (the "Company"). Below is... ► Artikel lesen | |
| 05.05. | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - March 2025 | 266 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 5, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - March... ► Artikel lesen | |
| 05.05. | AlzeCure Pharma AB: AlzeCure publishes its interim report for January - March 2025 | 129 | GlobeNewswire (Europe) | AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - March 2025 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/
"The... ► Artikel lesen | |
| 09.04. | Notice to Annual General Meeting in AlzeCure Pharma AB | 323 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 9, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - The shareholders of AlzeCure Pharma AB, reg. no. 559094-8302 (the "Company") are hereby invited to attend the... ► Artikel lesen | |
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| 07.04. | AlzeCure Pharma: New Data Bolstering the Anti-inflammatory Effect of NeuroRestore ACD856 Presented at Alzheimer's Conference | 321 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 7, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 03.04. | AlzeCure Pharma publishes its Annual Report for 2024 | 298 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 3, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 02.04. | AlzeCure Pharma: New Scientific Article in Nature Linking the Potential use of NeuroRestore ACD856 for the Treament of Obesity | 312 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 2, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 01.04. | AlzeCure Pharma to present at Redeye Theme: Alzheimer & Parkinsons on April 8 | 275 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 1, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 27.02. | AlzeCure Pharma: AlzeCure Publishes its Year-End Report for January - December 2024 | 714 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESS Newswire / February 27, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its Year-end report for the period January... ► Artikel lesen | |
| 24.02. | AlzeCure Pharma: New Article Showing the Unique Mechanism of Action Behind Alzstatin as an Alzheimer's Treatment | 343 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESS Newswire / February 24, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) ), a pharmaceutical company that develops candidate drugs for... ► Artikel lesen | |
| 17.02. | AlzeCure Pharma: AlzeCure Receives EU Grant for Phase 2 Clinical Trial of NeuroRestore ACD856 for Alzheimer's Disease | 348 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESS Newswire / February 17, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for... ► Artikel lesen | |
| 21.01. | AlzeCure Pharma: AlzeCure Receives Abstract Acceptance at Alzheimer's Congress AD/PD 2025 on NeuroRestore ACD856 | 394 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / January 21, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 27.11.24 | AlzeCure Pharma: AlzeCure to Present at the Pharma Outsourcing Conference in Stockholm | 393 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / November 27, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops small molecule drugs for... ► Artikel lesen | |
| 26.11.24 | AlzeCure Pharma to Present at Redeye Life Science Day on December 3 | 351 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / November 26, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 20.11.24 | AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm | 461 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / November 20, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 11.11.24 | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - September 2024 | 775 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / November 11, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - September... ► Artikel lesen | |
| 30.10.24 | AlzeCure Pharma: AlzeCure Presents New Anti-Inflammatory Data with NeuroRestore ACD856 at the Alzheimer's Conference CTAD | 539 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / October 30, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 28.10.24 | AlzeCure Pharma: AlzeCure Presents New Positive Data for the TrkA-NAM Pain Project Against Osteoarthritis | 340 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / October 28, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases... ► Artikel lesen |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 395,50 | +0,08 % | Vertex Pharmaceuticals Incorporated: Vertex Presents New Data on Benefits of ALYFTREK and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference | - Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with... ► Artikel lesen | |
| VIATRIS | 7,584 | -0,73 % | Viatris Reports Positive Top-line Results From LYNX-2 Phase 3 Trial With MR-142 | WASHINGTON (dpa-AFX) - Viatris (VTRS) reported positive top-line results from LYNX-2, a Phase 3 trial evaluating MR-142 in treating significant, chronic night driving impairment in keratorefractive... ► Artikel lesen | |
| OPKO HEALTH | 1,200 | +0,22 % | Opko Health auf Jefferies-Konferenz: Strategische Umstrukturierung und Wachstumspläne | ||
| JAGUAR HEALTH | 3,885 | -2,88 % | Jaguar Health, Inc.: Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series | Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 6, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate... ► Artikel lesen | |
| ALTIMMUNE | 5,060 | +2,70 % | Citizens JMP behält Altimmune-Aktienbewertung mit Kursziel von 25 US-Dollar bei | ||
| SELLAS LIFE SCIENCES | 1,430 | +1,42 % | SELLAS Life Sciences Group, Inc.: SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting | - ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer - - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 7,120 | -0,86 % | Aurinia Pharmaceuticals Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| KIORA PHARMACEUTICALS | 3,080 | -0,32 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia | Total potential deal value of $110 million plus royaltiesKiora to receive an immediate $1.25 million exclusive option feeIf the option is exercised, Kiora will receive an additional mid-single digit... ► Artikel lesen | |
| LIPOCINE | 3,110 | -2,05 % | Lipocine Inc. - 8-K, Current Report | ||
| PHOTOCURE | 4,230 | -0,24 % | Photocure ASA: Results for the first quarter of 2025 | OSLO, Norway, May 8, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 125.3 million in the first quarter of 2025 (Q1 2024: NOK 116.8 million)... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 1,416 | +5,12 % | Aclaris Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| EUROBIO SCIENTIFIC | 24,450 | +0,20 % | Eurobio Scientific: EB Development rises above 90% threshold | EB Development rises above 90% threshold Paris, May 19, 2024 - 7:00 pm - Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro medical diagnostics and life... ► Artikel lesen | |
| MEDICURE | 0,660 | -8,33 % | Medicure, Inc.: Medicure Reports Financial Results for Quarter Ended March 31, 2025 and Annual General Meeting Director Election Results | WINNIPEG, MB / ACCESS Newswire / May 21, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC Pink:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
| BAYER | 26,435 | +0,02 % | Bayer, Vidac Pharma, Evotec - schnappen Sie sich den 866 Milliarden Onkologie Jackpot | Die Onkologie erlebt eine beispiellose Revolution. Mit prognostizierten 866 Mrd. USD Marktvolumen bis 2034 und 11 % Jahreswachstum treiben KI-gestützte Diagnosen, personalisierte Gentherapien und Präzisionsmedizin... ► Artikel lesen | |
| MERCK KGAA | 115,20 | -0,17 % | Aktie von Merck legt um 0,83 Prozent zu (116,00 €) | Das Wertpapier von Merck notiert heute fester. Die Aktie kostete zuletzt 116,00 Euro. Heute hat sich am deutschen Aktienmarkt die Merck-Aktie zwischenzeitlich um 0,83 Prozent verteuert. Der Kurs des... ► Artikel lesen |
Das Unternehmen ALZECURE PHARMA AB kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,017 (-5,88 %) liegt der Kurs bei 0,272 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.